-
公开(公告)号：US20230033291A1
公开(公告)日：2023-02-02
申请号：US17809810
申请日：2022-06-29
IPC分类号： A61K51/04 , A61K47/54 , A61K31/4709 , A61K49/00
摘要： Excessive deposition of extracellular matrix is a hallmark of Idiopathic pulmonary fibrosis (IPF), it is advantageous to target the cells and the mechanisms associated with this process. By targeting myofibroblasts (specialized contractile fibroblasts) that are key for the development of IPF with drugs conjugated with fibroblast activation protein (FAP). this technology helps minimize the production of extracellular matrix in the lungs and provides a new treatment option for patients diagnosed with IPF.
-
公开(公告)号：US11426472B2
公开(公告)日：2022-08-30
申请号：US17285717
申请日：2019-10-15
IPC分类号： A61K51/04 , A61K47/54 , A61K31/4709 , A61K49/00
摘要： Excessive deposition of extracellular matrix is a hallmark of Idiopathic pulmonary fibrosis (IPF), it is advantageous to target the cells and the mechanisms associated with this process. By targeting myofibroblasts (specialized contractile fibroblasts) that are key for the development of IPF with drugs conjugated with fibroblast activation protein (FAP), this technology helps minimize the production of extracellular matrix in the lungs and provides a new treatment option for patients diagnosed with IPF.
-
公开(公告)号：US20240165279A1
公开(公告)日：2024-05-23
申请号：US18395366
申请日：2023-12-22
IPC分类号： A61K51/04 , A61K31/4709 , A61K47/54 , A61K49/00
CPC分类号： A61K51/0482 , A61K31/4709 , A61K47/545 , A61K49/0043
摘要： Excessive deposition of extracellular matrix is a hallmark of Idiopathic pulmonary fibrosis (IPF); it is advantageous to target the cells and the mechanisms associated with this process. By targeting myofibroblasts (specialized contractile fibroblasts) that are key for the development of IPF with drugs conjugated with fibroblast activation protein (FAP), this technology helps minimize the production of extracellular matrix in the lungs and provides a new treatment option for patients diagnosed with IPF.
-
公开(公告)号：US11890357B2
公开(公告)日：2024-02-06
申请号：US17809810
申请日：2022-06-29
IPC分类号： A61K51/04 , A61K47/54 , A61K31/4709 , A61K49/00
CPC分类号： A61K51/0482 , A61K31/4709 , A61K47/545 , A61K49/0043
摘要： Excessive deposition of extracellular matrix is a hallmark of Idiopathic pulmonary fibrosis (IPF), it is advantageous to target the cells and the mechanisms associated with this process. By targeting myofibroblasts (specialized contractile fibroblasts) that are key for the development of IPF with drugs conjugated with fibroblast activation protein (FAP), this technology helps minimize the production of extracellular matrix in the lungs and provides a new treatment option for patients diagnosed with IPF.
-
公开(公告)号：US11883498B2
公开(公告)日：2024-01-30
申请号：US17065737
申请日：2020-10-08
发明人： Philip Stewart Low , Jyoti Roy
CPC分类号： A61K47/545 , A61K38/09 , A61K45/06 , A61K47/65 , A61K49/0021 , A61P35/00
摘要： The present teachings relate generally to conjugates and methods for imaging a tumor microenvironment in a patient, and to conjugates and methods for treating LHRH-R expressing cancer in a patient. The present teachings relate generally to method of making conjugates comprising an LHRH-R antagonist.
-
公开(公告)号：US11872291B2
公开(公告)日：2024-01-16
申请号：US17245872
申请日：2021-04-30
发明人： Philip Stewart Low , Jyoti Roy
IPC分类号： A61K51/04 , A61K47/55 , A61K49/00 , G01N33/569
CPC分类号： A61K51/0497 , A61K47/55 , A61K49/0032 , A61K49/0043 , A61K49/0052 , G01N33/56966
摘要： The present teachings relate generally to conjugates and methods for imaging a tumor microenvironment in a patient, and to conjugates and methods for imaging cancer-associated fibroblasts (CAFs) in the tumor microenvironment of a patient. The present teachings relate generally to method of making conjugates comprising a fibroblast activation protein (FAP) inhibitor.
-
公开(公告)号：US20220001037A1
公开(公告)日：2022-01-06
申请号：US17285717
申请日：2019-10-15
IPC分类号： A61K51/04 , A61K49/00 , A61K31/4709 , A61K47/54
摘要： Excessive deposition of extracellular matrix is a hallmark of Idiopathic pulmonary fibrosis (IPF), it is advantageous to target the cells and the mechanisms associated with this process. By targeting myofibroblasts (specialized contractile fibroblasts) that are key for the development of IPF with drugs conjugated with fibroblast activation protein (FAP), this technology helps minimize the production of extracellular matrix in the lungs and provides a new treatment option for patients diagnosed with IPF.
-
公开(公告)号：US10821188B2
公开(公告)日：2020-11-03
申请号：US16469906
申请日：2017-12-13
发明人： Philip Stewart Low , Jyoti Roy
摘要： The present teachings relate generally to conjugates and methods for imaging a tumor microenvironment in a patient, and to conjugates and methods for treating LHRH-R expressing cancer in a patient. The present teachings relate generally to method of making conjugates comprising an LHRH-R antagonist.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.016 秒)
